Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : BESREMi
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 23, 2024
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 05, 2024
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : ANOVA CRO | PharmaLex | Aixial s.r.o. | GCP-Service International
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2024
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : ANOVA CRO | PharmaLex | Aixial s.r.o. | GCP-Service International
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Landiolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Eagle Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Eagle Announces Licensing Agreement with AOP Orphan for Landiolol
Details : The Company will support the submission of a new drug application to the U.S. FDA seeking approval for Landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flut...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $5.0 million
September 08, 2021
Lead Product(s) : Landiolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Eagle Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 28, 2016
Lead Product(s) : Pegylated-Proline-Interferon alpha-2b
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : PharmaEssentia
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 14, 2015
Lead Product(s) : Pegylated-Proline-Interferon alpha-2b
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : PharmaEssentia
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegproline Interferon Alfa-2b
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : PharmaEssentia
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 15, 2014
Lead Product(s) : Pegproline Interferon Alfa-2b
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : PharmaEssentia
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anagrelide Retard in Essential Thrombocythemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2014
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Interferon Alfa-2B
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : PharmaEssentia
Deal Size : Inapplicable
Deal Type : Inapplicable
Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 25, 2013
Lead Product(s) : Interferon Alfa-2B
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : PharmaEssentia
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Arbeitsgemeinschaft medikamentöse Tumortherapie
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 02, 2013
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Arbeitsgemeinschaft medikamentöse Tumortherapie
Deal Size : Inapplicable
Deal Type : Inapplicable